TScan Therapeutics Inc (TCRX): Narx/daromad koeffitsiyenti

tscan.com (TCRX) kompaniyasining korporativ logotipi

Yuqori R&D xarajatlari va qat'iy FDA tartib-qoidalari TScan Therapeutics (TCRX) raqobatchilari uchun yengib bo'lmas kirish to'sig'ini yaratadi. Daromad multiplikatori dinamikasi joriy bozor holatini aks ettiradi, bunda 1.50 darajasi parametrning holatini ko'rsatadi. O'sish TCR-T sinovlaridagi muvaffaqiyatlar va sog'liqni saqlash gigantlarining qiziqishi bilan ta'minlanmoqda, ishlanmalar esa moliyaviy rag'batlar va ilmiy erkinlik bilan motivatsiya qilingan ekspertlar jamoasi tomonidan qo'llab-quvvatlanmoqda.

TCRX tscan.com: P/S multiplikatori 04.07.2022 - 13.11.2026 oraligʻida

TScan Therapeutics (TCRX) - koʻrsatkichlar kesimi va moliyaviy hisobotlar

- kotirovkalar va tahlilchilar prognozi:
Narx tscan.com|TCRX - Maqsadli narxlar grafigi
- birja kapitallashuvi ma'lumotlari:
Bozor kapitallashuvi TScan|TCRX - Korxona qiymati
- kompaniyaning balans qiymati tafsilotlari:
Bitta aksiya uchun buxgalteriya qiymati TScan Therapeutics|TCRX - Balans kapitallashuvi|Bozor kapitallashuvining balans qiymatiga nisbati tscan.com|TCRX - Kompaniyaning jami aktivlari
- qarz majburiyatlari va likvidlik statistikasi:
Qarzning xususiy kapitalga nisbati TScan Therapeutics|TCRX - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzdorlikning kapitalga nisbati tscan.com|TCRX - Kompaniyaning umumiy qarzi|Qarzning balans kapitaliga nisbati TScan|TCRX - Kompaniyaning uzoq muddatli qarzlari|Kompaniyaning qisqa muddatli kredit va qarzlari TScan Therapeutics|Shoshilinch likvidlik tscan.com
- biznes foydasi va investitsiya koeffitsiyentlari ma'lumotlari:
TCRX - Kompaniyaning sof foydasi|Kutilayotgan sof daromad TScan Therapeutics|TCRX - P/E multiplikatori|Forvard P/E multiplikatori tscan.com|TCRX - Narxning foydaga va o‘sish sur’atiga nisbati|Kompaniya qiymatining amortizatsiyadan oldingi operatsion foydaga nisbati TScan|TCRX - EBITDA operatsion foydasi|So'nggi o'n ikki oy davomida bitta aksiya uchun sof foyda TScan Therapeutics|TCRX - So'nggi 12 oy davomida bir aksiya uchun sof foyda|Choraklik EPS foyda o'sishi tscan.com|TCRX - Bu yil bir aksiya uchun sof foyda o'sishi|Keyingi yilda bir aksiya uchun foydaning prognoz qilingan ortishi TScan Therapeutics
- emitentning tushumi va sotuvlari tafsilotlari:
TCRX - Daromad va sotish hajmi|Kompaniyaning kelajakdagi savdosi tscan.com|TCRX - P/S multiplikatori|Forvard narx/daromad multiplikatori TScan
Kompaniyaning jamlanma tahliliyoti:TScan Therapeutics Inc
TScan Therapeutics, Inc. tomonidan chiqariladigan mahsulotlar

P/S koeffitsienti biznesning bozor qiymatini uning yillik daromadiga nisbatan aniqlaydi va kelajakdagi o'sish uchun premiumni o'lchaydi. Ushbu hisob-kitob aktivlar haddan tashqari qimmat yoki arzon baholanganini aniqlash uchun bozor kapitalizatsiyasini haqiqiy pul oqimlari bilan solishtiradi. GURU.Markets platformasidagi joriy P/S darajasini tahlil qilish orqali investor xavf va daromad potentsiali o'rtasidagi muvozanatni baholaydi. TScan Therapeutics (TCRX) uchun ushbu ko'rsatkich qattiq o'simtalar terapiyasini kengaytirishga oid bozor kutganlarini aks ettiradi.

Raqobatdosh kompaniyalar

Kapitalizatsiyaning sotish hajmiga nisbati ONC|Narxning daromadga nisbati Halozyme HALO|Narx/daromad koeffitsiyenti Revolution Medicines Inc (RVMD)|Ascentage - P/S multiplikatori|CG Oncology Therapeutics (CGON) - Kapitalizatsiyaning daromadga nisbati|URGN: P/S multiplikatori|bicara.com (BCAX) - P/S multiplikatori|Narxning daromadga nisbati Personalis|Kapitalizatsiya va daromad nisbati ERAS (Erasca Inc)|Kapitalizatsiyaning daromadga nisbati DCTH (Delcath)|YMAB (Y-mAbs Corp) - Bozor kapitallashuvining daromadga nisbati|Aura Biosciences, Inc. - Kapitalizatsiyaning daromadga nisbati|Kapitalizatsiyaning sotish hajmiga nisbati CADL (Candel Therapeutics Inc.)|Accuray - P/S multiplikatori|Bozor kapitallashuvining daromadga nisbati SLS (SELLAS Life Sciences)|ACTU: P/S multiplikatori|Sotuvga nisbatan narx Citius Oncology Inc (CTOR)|Narxning daromadga nisbati TuHURA Biosciences Inc.|TARA: Bozor kapitallashuvining daromadga nisbati|P/S multiplikatori FATE|P/S multiplikatori aadibio.com (WHWK)|Narxning daromadga nisbati Champions Oncology, Inc. CSBR|XBIT (XBiotech Inc) - Narxning sotuvga nisbati|CEL-SCI Corp - P/S multiplikatori|Sotuvga nisbatan narx ostherapies.com|RADX (Radiopharm Theranostics) - Kapitalizatsiyaning daromadga nisbati|Artiva Biotherapeutics (ARTV) - P/S multiplikatori|Kapitalizatsiyaning daromadga nisbati ANL|VERU (Veru Corporation) - Kapitalizatsiyaning sotish hajmiga nisbati|P/S multiplikatori TPST|Narx/daromad koeffitsiyenti xiliotx.com|P/S multiplikatori RENB (Renovaro)|MURA - Kapitalizatsiyaning daromadga nisbati|KAPA - Narxning daromadga nisbati|Narx/daromad koeffitsiyenti OnKure Therapeutics Inc OKUR|GDTC (w2.cytomed.sg) - Kapitalizatsiyaning daromadga nisbati|CRIS: Kapitalizatsiyaning sotish hajmiga nisbati|APLM (Apollomics Inc.) - P/S multiplikatori|Kapitalizatsiyaning daromadga nisbati Tharimmune Inc (THAR)|Narxning daromadga nisbati Advanced Biomed Inc (ADVB)|GNPX (Genprex Inc) - Bozor kapitallashuvining daromadga nisbati|Calidi Biotherapeutics, Inc. - Kapitalizatsiyaning daromadga nisbati|SBFM: Kapitalizatsiya va daromad nisbati|Xenetic Bio - P/S multiplikatori|Salarius Pharmaceuticals Inc (SLRX) - Kapitalizatsiyaning daromadga nisbati|PPBT: P/S multiplikatori|American Oncology Network, Inc. (AONC) - P/S multiplikatori|Narxning daromadga nisbati BeiGene, Ltd.|Kapitalizatsiya va daromad nisbati CKPT (checkpointtx.com)|P/S multiplikatori ELEV|Kapitalizatsiyaning daromadga nisbati icadmed.com ICAD|P/S multiplikatori IKNA (Ikena Oncology)|Notable Labs Corp (NTBL) - Sotuvga nisbatan narx|VIRX - Narxning daromadga nisbati|Bozor kapitallashuvining daromadga nisbati MOR (morphosys.com)|NAYA (NAYA Biosciences Inc.) - Kapitalizatsiyaning daromadga nisbati|Ascentage Pharma Group International - Bozor kapitallashuvining daromadga nisbati